JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A2307 PHA-665752
1 Citation

Target: c-MET

Summary: C-Met inhibitor,potent and ATP-competitive
A2678 SU11274
2 Citation

Target: MET

Summary: C-Met inhibitor,potent and selective

≥28.4 mg/mL
A5096 PF-04217903

Target: c-MET

Summary: C-Met inhibitor,selective and ATP-competitive

insoluble in EtOH; insoluble in H2O; ≥18.6 mg/mL
A1196 SGX-523
1 Citation

Target: MET

Summary: MET inibitor, highly selective, ATP-competitive

≥17.95 mg/mL
A5703 BMS-777607

Target: MET

Summary: C-Met inhibitor, potent and selective

≥25.65 mg/mL
A8325 Tivantinib (ARQ 197)
2 Citation

Target: MET

Summary: C-Met inhibitor,non-ATP-competitive

≥18.47 mg/mL
A8448 INCB28060

Target: c-MET

Summary: C-Met inhibitor,ATP-competitive and novel

insoluble in EtOH; insoluble in H2O; ≥5.15 mg/mL
B5832 Altiratinib
1 Citation

Target: FLT3|VEGFR|Trk Receptors|c-MET|Tie-2

Summary: c-MET/TIE-2/VEGFR inhibitor

≥21.55 mg/mL
B1438 BMS-794833

Target: MET|Flk-1

Summary: Met/VEGFR-2 inhibitor,potent and ATP-competitive

≥23.45 mg/mL
A3020 (R)-Crizotinib
2 Citation

Target: c-MET

Summary: C-MET/ALK inhibitor,potent and ATP-competitve

insoluble in H2O; insoluble in EtOH; ≥7.51 mg/mL